10.19.10
Epax AS confirmed that its DHA-rich 1050 TG formula is currently being studied for its potential effect on metabolic syndrome and its associated conditions. BIOCLAIMS, a scientific program that supports European university researchers and is funded by the Seventh EU (European Union) Framework Program, will oversee a series of studies conducted through 2013 to determine what role marine-derived DHA plays on health factors such as central (waist) obesity, elevated blood pressure and triglyceride levels, as well as prevalence of insulin resistance (a precursor to type II diabetes).
The program’s first study has commenced under the direction of professor Aldona Dembinska-Kiec of the University of Poland, Krakow, who has designed a double-blind, placebo-controlled study involving 300 patients to analyze several metabolic syndrome health markers. For further information: www.epax.com
The program’s first study has commenced under the direction of professor Aldona Dembinska-Kiec of the University of Poland, Krakow, who has designed a double-blind, placebo-controlled study involving 300 patients to analyze several metabolic syndrome health markers. For further information: www.epax.com